PURPOSE: Thalidomide and lenalidomide are immunomodulatory drugs (IMiDs) that produce high remission rates in the treatment of multiple myeloma. Pomalidomide is a new IMiD with high in vitro potency. We report, to our knowledge, the first phase II trial of pomalidomide administered in combination with low-dose dexamethasone for the treatment of relapsed or refractory multiple myeloma. PATIENTS AND METHODS: Pomalidomide was administered orally at a dose of 2 mg daily on days 1 through 28 of a 28-day cycle. Dexamethasone 40 mg daily was administered orally on days 1, 8, 15, and 22 of each cycle. Responses were recorded using the criteria of the International Myeloma Working Group. RESULTS: Sixty patients were enrolled. Thirty-eight patients (63%) achieved confirmed response including complete response in three patients (5%), very good partial response in 17 patients (28%), and partial response in 18 patients (30%). Responses were seen in 40% of lenalidomide-refractory patients, 37% of thalidomide-refractory patients, and 60% of bortezomib-refractory patients. Responses were seen in 74% of patients with high-risk cytogenetic or molecular markers. Toxicity consisted primarily of myelosuppression. Grade 3 or 4 hematologic toxicity consisted of anemia (5%), thrombocytopenia (3%), and neutropenia (32%). One patient (1.6%) had a thromboembolic event. The median progression-free survival time was 11.6 months and was not significantly different in patients with high-risk disease compared with patients with standard-risk disease. CONCLUSION: The combination of pomalidomide and low-dose dexamethasone is extremely active in the treatment of relapsed multiple myeloma, including high response rates in patients refractory to other novel agents.
PURPOSE:Thalidomide and lenalidomide are immunomodulatory drugs (IMiDs) that produce high remission rates in the treatment of multiple myeloma. Pomalidomide is a new IMiD with high in vitro potency. We report, to our knowledge, the first phase II trial of pomalidomide administered in combination with low-dose dexamethasone for the treatment of relapsed or refractory multiple myeloma. PATIENTS AND METHODS: Pomalidomide was administered orally at a dose of 2 mg daily on days 1 through 28 of a 28-day cycle. Dexamethasone 40 mg daily was administered orally on days 1, 8, 15, and 22 of each cycle. Responses were recorded using the criteria of the International Myeloma Working Group. RESULTS: Sixty patients were enrolled. Thirty-eight patients (63%) achieved confirmed response including complete response in three patients (5%), very good partial response in 17 patients (28%), and partial response in 18 patients (30%). Responses were seen in 40% of lenalidomide-refractory patients, 37% of thalidomide-refractory patients, and 60% of bortezomib-refractory patients. Responses were seen in 74% of patients with high-risk cytogenetic or molecular markers. Toxicity consisted primarily of myelosuppression. Grade 3 or 4 hematologic toxicity consisted of anemia (5%), thrombocytopenia (3%), and neutropenia (32%). One patient (1.6%) had a thromboembolic event. The median progression-free survival time was 11.6 months and was not significantly different in patients with high-risk disease compared with patients with standard-risk disease. CONCLUSION: The combination of pomalidomide and low-dose dexamethasone is extremely active in the treatment of relapsed multiple myeloma, including high response rates in patients refractory to other novel agents.
Authors: Hakan Kaya; Benjamin Peressini; Irfan Jawed; Danko Martincic; Ameer L Elaimy; Wayne T Lamoreaux; Robert K Fairbanks; Kevin A Weeks; Christopher M Lee Journal: Int J Hematol Date: 2011-12-09 Impact factor: 2.490
Authors: Rafael Fonseca; Paul Richardson; Sergio Giralt; Sagar Lonial; S Vincent Rajkumar; A Keith Stewart; William Bensinger; George Somlo; Robert Vescio; Joseph Mikhael; Craig Reeder; Rodger Tiedemann; Guido Tricot; Robert Rifkin; John Shaughnessy; Nikhil Munshi; Noopur Raje; Irene Ghobrial; Jacob Laubach; Robert Schlossman; Steven Treon; Anuj Mahindra; David Avigan; Jacalyn Rosenblatt; Sundar Jagannath; Ruben Niesvizky; Heather Landau; Selina Chen-Kiang; David S Siegel; Todd Zimmerman; Jayesh Mehta; David Vesole; Steven Rosen; Craig Hofmeister; Martha Lacy; Angela Dispenzieri; Ivan Borrello; Suzanne R Hayman; Shaji Kumar; Frances Buadi; David Dingli; Stephen Russell; Melissa Alsina Melissa Alsina; Hugo Fernandez; Vivek Roy; Denise Pereira; Edward Stadtmauer; Ravi Vij; Andrzej Jakubowiak; Suzanne Lentzsch; Kevin Song; Suzanne Trudel; Christine Chen; Donna Reece; Douglas Stewart; Seema Singhal; Raymond Comenzo; Morie A Gertz; Philip R Greipp; Brian Durie; Bart Barlogie; Kenneth Anderson; William Dalton; Morton Coleman; Susie Novis; Robert A Kyle Journal: Mayo Clin Proc Date: 2010-02 Impact factor: 7.616
Authors: Chris Mahony; Lynda Erskine; Jennifer Niven; Nigel H Greig; William Douglas Figg; Neil Vargesson Journal: Proc Natl Acad Sci U S A Date: 2013-07-15 Impact factor: 11.205
Authors: Steven R Schuster; K Martin Kortuem; Yuan Xiao Zhu; Esteban Braggio; Chang-Xin Shi; Laura A Bruins; Jessica E Schmidt; Greg Ahmann; Shaji Kumar; S Vincent Rajkumar; Joseph Mikhael; Betsy Laplant; Mia D Champion; Kristina Laumann; Bart Barlogie; Rafael Fonseca; P Leif Bergsagel; Martha Lacy; A Keith Stewart Journal: Leuk Res Date: 2013-09-05 Impact factor: 3.156
Authors: A K Nooka; J L Kaufman; S Muppidi; A Langston; L T Heffner; C Gleason; D Casbourne; D Saxe; L H Boise; S Lonial Journal: Leukemia Date: 2013-11-13 Impact factor: 11.528
Authors: S Ailawadhi; J R Mikhael; B R LaPlant; K M Laumann; S Kumar; V Roy; D Dingli; P L Bergsagel; F K Buadi; S V Rajkumar; R Fonseca; M A Gertz; P Kapoor; T Sher; S R Hayman; A K Stewart; A Dispenzieri; R A Kyle; W I Gonsalves; C B Reeder; Y Lin; R S Go; N Leung; T Kourelis; J A Lust; S J Russell; A A Chanan-Khan; M Q Lacy Journal: Leukemia Date: 2017-09-01 Impact factor: 11.528
Authors: Chelsea E Powell; Guangyan Du; Jianwei Che; Zhixiang He; Katherine A Donovan; Hong Yue; Eric S Wang; Radosław P Nowak; Tinghu Zhang; Eric S Fischer; Nathanael S Gray Journal: ACS Chem Biol Date: 2020-09-28 Impact factor: 5.100
Authors: Paul G Richardson; David Siegel; Rachid Baz; Susan L Kelley; Nikhil C Munshi; Jacob Laubach; Daniel Sullivan; Melissa Alsina; Robert Schlossman; Irene M Ghobrial; Deborah Doss; Nora Loughney; Laura McBride; Elizabeth Bilotti; Palka Anand; Lisa Nardelli; Sandra Wear; Gail Larkins; Min Chen; Mohamad H Zaki; Christian Jacques; Kenneth C Anderson Journal: Blood Date: 2012-12-14 Impact factor: 22.113